Nanomedicine : nanotechnology, biology, and medicine最新文献_第4页

Efficient gene delivery to immune cells via a recombinant multifunctional chimeric peptide nanocarrier: Implications in immunotherapy 通过重组多功能嵌合肽纳米载体有效地向免疫细胞传递基因：在免疫治疗中的意义

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-06-16 DOI: 10.1016/j.nano.2025.102837

Mahdiyar Dehshiri MSc , Fateme Zarein MSc , Fatemeh Rajabi MSc , Mohammad Reza Javan PhD , Maryam Nikkhah PhD , Fatemeh Rahbarizadeh PhD , Jalil Mehrzad PhD, DVM , Seyed Mohammad Moazzeni PhD , Amir Ali Hamidieh MD , Saman Hosseinkhani PhD

{"title":"Efficient gene delivery to immune cells via a recombinant multifunctional chimeric peptide nanocarrier: Implications in immunotherapy","authors":"Mahdiyar Dehshiri MSc , Fateme Zarein MSc , Fatemeh Rajabi MSc , Mohammad Reza Javan PhD , Maryam Nikkhah PhD , Fatemeh Rahbarizadeh PhD , Jalil Mehrzad PhD, DVM , Seyed Mohammad Moazzeni PhD , Amir Ali Hamidieh MD , Saman Hosseinkhani PhD","doi":"10.1016/j.nano.2025.102837","DOIUrl":"10.1016/j.nano.2025.102837","url":null,"abstract":"<div><div>Genetic modification of immune cells remains a major challenge in immunotherapy. While viral and non-viral carriers exist, low gene transfer efficiency persists with non-viral methods. We present a peptide-based carrier (MiRGD) for gene delivery to diverse immune cells. The MiRGD/plasmid complex formation was characterized via gel retardation, dynamic light scattering, and zeta potential analysis. After safety and efficiency optimization in HEK293T cells, MiRGD achieved 69 % chimeric antigen receptor (CAR) transfection in Jurkat T cells (>98 % viability) and 28 % in primary human T cells. Dendritic cells showed 61 % transfection with >85 % viability. In vivo, MiRGD functioned as a DNA vaccine against SARS-CoV-2, eliciting robust antibody titers, neutralization, and safe histopathology. These results demonstrate MiRGD's efficacy and biocompatibility for immune cell engineering (T cells, dendritic cells, macrophages) and vaccination, offering a cost-effective, non-toxic platform for immunotherapy applications.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"68 ","pages":"Article 102837"},"PeriodicalIF":4.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144322453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel theranostic system of PD-L1-Aptamer-functionalized fluorescent silica nanoparticles for triple-negative breast cancer pd - l1适配体功能化荧光二氧化硅纳米颗粒治疗三阴性乳腺癌的新系统

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-06-13 DOI: 10.1016/j.nano.2025.102834

Juntao Tan MD , Daqing Zhu MD , Guobiao Li MD , Hai Hu MD , Zongqiang Lai MD , Zhihua Li MD

{"title":"A novel theranostic system of PD-L1-Aptamer-functionalized fluorescent silica nanoparticles for triple-negative breast cancer","authors":"Juntao Tan MD , Daqing Zhu MD , Guobiao Li MD , Hai Hu MD , Zongqiang Lai MD , Zhihua Li MD","doi":"10.1016/j.nano.2025.102834","DOIUrl":"10.1016/j.nano.2025.102834","url":null,"abstract":"<div><h3>Background</h3><div>Triple-negative breast cancer (TNBC) lacks effective targeted therapies due to absent hormone receptors and HER2 expression, often resulting in poor prognosis. This study developed a theranostic system, AptPD-L1-FSNPs, combining PD-L1 aptamers with fluorescent silica nanoparticles (FSNPs) for targeted imaging and therapy in TNBC.</div></div><div><h3>Methods</h3><div>PD-L1 aptamers were conjugated to FSNPs, forming AptPD-L1-FSNPs. <em>In vitro</em> binding was evaluated using PD-L1-positive TNBC cells and negative controls. <em>In vivo</em> tumor targeting and biodistribution were assessed <em>via</em> fluorescence imaging in TNBC-bearing mice. Therapeutic efficacy was measured by tumor growth inhibition, survival, and apoptosis, with toxicity assessed in major organs.</div></div><div><h3>Results</h3><div>AptPD-L1-FSNPs showed high specificity to PD-L1-expressing TNBC cells and prolonged tumor retention <em>in vivo</em>. Treatment led to reduced tumor growth, increased apoptosis, and improved survival with minimal toxicity.</div></div><div><h3>Conclusion</h3><div>AptPD-L1-FSNPs offer targeted TNBC imaging and therapeutic potential, demonstrating promise for future clinical applications in personalized cancer treatment.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"68 ","pages":"Article 102834"},"PeriodicalIF":4.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144291512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of nanoparticles and quantum dots as alternatives to iodinated contrast agents for mono-modal and bi-modal computed tomography imaging 纳米粒子和量子点的发展作为碘造影剂的替代品用于单峰和双峰计算机断层成像。

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-06-12 DOI: 10.1016/j.nano.2025.102831

Ammar Alhasan PhD , S.F. Abdul Sani PhD , Hairul Anuar Tajuddin PhD , Tammar Hussein Ali PhD

{"title":"Development of nanoparticles and quantum dots as alternatives to iodinated contrast agents for mono-modal and bi-modal computed tomography imaging","authors":"Ammar Alhasan PhD , S.F. Abdul Sani PhD , Hairul Anuar Tajuddin PhD , Tammar Hussein Ali PhD","doi":"10.1016/j.nano.2025.102831","DOIUrl":"10.1016/j.nano.2025.102831","url":null,"abstract":"<div><div>Medical imaging plays a pivotal role in disease screening, early detection, and diagnosis. Among the various imaging modalities, computed tomography (CT) is one of the most widely utilized in clinical practice, offering high-resolution anatomical images critical for disease investigation. To enhance the visibility of tissues with similar densities, contrast agents are often required. Iodinated contrast agents, the most commonly used, are effective but have significant limitations, including short circulation times, the need for high-concentration injections, restricted tissue targeting, and potential side effects such as nephrotoxicity. These challenges have spurred the development of next-generation contrast agents. Nanostructured materials, particularly nanoparticles and quantum dots, have emerged as promising alternatives due to their superior X-ray attenuation, extended circulation times, and potential for multi-modal imaging applications such as CT/MRI and CT/fluorescence. Their unique properties, including small size, large surface area, and tunable functionalization enable targeted imaging and reduced side effects, making them ideal candidates for advanced diagnostics. This review highlights the recent advancements in synthesizing and optimizing nanostructured contrast agents based on their elemental composition, synthesis techniques, and imaging properties. It underscores the transformative potential of nano-based agents in enhancing diagnostic accuracy while minimizing adverse effects, marking a significant step forward in medical imaging technology.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"68 ","pages":"Article 102831"},"PeriodicalIF":4.2,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144294140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “novel pH-responsive E-selectin targeting natural polysaccharides hybrid micelles for diabetic nephropathy” [nanomedicine: nanotechnology, biology and medicine, volume 52, august 2023, 102,696] “针对糖尿病肾病的天然多糖混合胶束的新型ph反应性e -选择素”的更正[纳米医学：纳米技术，生物学和医学，第52卷，2023年8月，102,696]

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-06-12 DOI: 10.1016/j.nano.2025.102832

Ph.D Chunjing Guo , MD Min Cao , MD Ningning Diao , MD Wenxin Wang , MD Hongxu Geng , MD Yanguo Su , BD Tianying Sun , BD Xinyue Lu , Ph.D Ming Kong , Ph.D Daquan Chen

引用次数: 0

Self-assembled nanomedicine of the conjugate based on Ce6 and chrysin improves photodynamic performance 基于Ce6和菊花素共轭物的自组装纳米药物提高了光动力性能。

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-06-10 DOI: 10.1016/j.nano.2025.102836

Dr. Mingfa Xie, Dr. Shijie Yuan, Dr. Guangsong Li, Prof. Hongjian Peng

引用次数: 0

Surface-modified 99mTc-Lactoferrin nanoparticles as tracers for sentinel lymph node mapping 表面修饰的99mtc -乳铁蛋白纳米颗粒作为前哨淋巴结定位的示踪剂。

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-06-10 DOI: 10.1016/j.nano.2025.102835

Sanjay Kulkarni PhD , Anuj Kumar MSc , Soji Soman PhD , Abhijeet Pandey PhD , Suresh Subramanian PhD , Srinivas Mutalik PhD

{"title":"Surface-modified 99mTc-Lactoferrin nanoparticles as tracers for sentinel lymph node mapping","authors":"Sanjay Kulkarni PhD , Anuj Kumar MSc , Soji Soman PhD , Abhijeet Pandey PhD , Suresh Subramanian PhD , Srinivas Mutalik PhD","doi":"10.1016/j.nano.2025.102835","DOIUrl":"10.1016/j.nano.2025.102835","url":null,"abstract":"<div><div>We had previously examined the use of radioactive technetium-99m (Tc-99m)-labelled lactoferrin nanoparticles (LF-NPs) for sentinel lymph node (SLN) mapping. Compared with commercial tracer based on human serum albumin, LF-NPs exhibited better size uniformity and reduced batch variation. However, while in vitro tests with <sup>99m</sup>Tc-LF-NPs in RAW 264.7 macrophages were promising, the in vivo results revealed poor accumulation in the SLNs. To improve their in vivo performance, we performed surface modification of LF-NPs with different agents, including polyethylene glycol (PEG). Characterisation studies revealed that PEGylated LF-NPs (LF-NP@PEG) were the most effective. In vitro tests revealed significantly greater cellular uptake of LF-NP@PEG than unmodified LF-NPs. In vivo evaluation in animal model demonstrated increased SLN uptake and retention, which was supported by scintigraphic imaging studies. Although further refinements are needed, these findings suggest potential application for modified LF-NPs in SLN detection.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"68 ","pages":"Article 102835"},"PeriodicalIF":4.2,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144285770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “enhanced chemo-immunotherapy against melanoma by inhibition of cholesterol esterification in CD8+ T cells” [nanomedicine: nanotechnology, biology, and medicine 14 (2018) 2541–2550] “通过抑制CD8+ T细胞中的胆固醇酯化来增强抗黑色素瘤的化学免疫疗法”的更正[纳米医学：纳米技术，生物学和医学14 (2018)2541-2550]

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-06-05 DOI: 10.1016/j.nano.2025.102833

Man Li PhD, Yuting Yang PhD, Jiaojie Wei Master of Science, Xingli Cun PhD, Zhengze Lu PhD, Yue Qiu PhD, Zhirong Zhang PhD, Qin He PhD

引用次数: 0

Corrigendum to “Construction of bionanoparticles based on Angelica polysaccharides for the treatment of stroke” [Nanomed: Nanotechnol Biol Med, volume 44, August 2022, 102570] “基于当归多糖的生物纳米粒子的构建用于治疗中风”的勘误表[Nanomed: nanotechnology Biol Med， vol . 44, August 2022, 102570]

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-06-02 DOI: 10.1016/j.nano.2025.102830

MD Yanguo Su , MD Chunjing Guo , MD Qiang Chena , MD Huimin Guo , BD Jinqiu Wang , BD Kaihang Mu , Ph.D Daquan Chen

引用次数: 0

Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer 基于Dar衍生物的前列腺癌grpr靶向PET探针的设计与合成

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-05-22 DOI: 10.1016/j.nano.2025.102829

Xiangning Luo BS , Renli Luo MS , Yuanyuan Zhou BS , Yuanpeng Jiang BS , Cong Han BS , Aiguo Song PhD , Kun Qian PhD , Chunrong Qu PhD , Rui Cao PhD , Bin Xu PhD , Zhen Cheng PhD

{"title":"Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer","authors":"Xiangning Luo BS , Renli Luo MS , Yuanyuan Zhou BS , Yuanpeng Jiang BS , Cong Han BS , Aiguo Song PhD , Kun Qian PhD , Chunrong Qu PhD , Rui Cao PhD , Bin Xu PhD , Zhen Cheng PhD","doi":"10.1016/j.nano.2025.102829","DOIUrl":"10.1016/j.nano.2025.102829","url":null,"abstract":"<div><div>Gastrin-releasing peptide receptor (GRPR) is overexpressed in most prostate cancers (PCa) and is a potential target in diagnosis and treatment. In this study, based on the previously reported GRPR antagonist RM26 and novel chelating agent Dar derivatives, we designed and evaluated two radiopharmaceuticals, [<sup>68</sup>Ga]Ga-Dar-C5-P2-RM26 and [<sup>68</sup>Ga]Ga-Dar-P2-RM26. Both radiotracers were easily prepared at room temperature and showed high radiochemical stability in phosphate-buffered saline (PBS) and fetal bovine serum (FBS). Cellular and animal experiments indicated that the two radiotracers exhibited specific tumor uptakes in PC-3 xenograft mice models. Specifically, [<sup>68</sup>Ga]Ga-Dar-C5-P2-RM26 and [<sup>68</sup>Ga]Ga-Dar-P2-RM26 displayed 6.617 ± 0.245 % ID/g and 5.973 ± 1.261 % ID/g tumor uptake, respectively. Positron emission tomography/ computer tomography (PET/CT) imaging results indicated that these two radiotracers showed excellent tumor-to-background contrast at 0.5 h, 1 h, and 2 h post intravenous injection (p.i.). In summary, [<sup>68</sup>Ga]Ga-Dar-C5-RM26 and [<sup>68</sup>Ga]Ga-Dar-RM26 are GRPR-targeted radiotracers with high potential for clinical translation in tumor-targeted imaging.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"67 ","pages":"Article 102829"},"PeriodicalIF":4.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential of plasma-derived medium-sized extracellular vesicles as a biopsy alternative for active surveillance decisions in prostate Cancer 血浆来源的中型细胞外囊泡作为前列腺癌主动监测决策的活检选择的潜力。

IF 4.2 2区医学

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2025-05-11 DOI: 10.1016/j.nano.2025.102828

Kamil Szeliski PhD , Zuzanna Fekner MSc , Damian Kasiński MSc , Marta Rasmus MSc , Filip Kowalski MD, PhD , Milena Świtońska Assoc. Prof. , Katarzyna Sierakowska Assoc. Prof. , Tomasz Drewa Prof. , Marta Pokrywczyńska Prof.

{"title":"The potential of plasma-derived medium-sized extracellular vesicles as a biopsy alternative for active surveillance decisions in prostate Cancer","authors":"Kamil Szeliski PhD , Zuzanna Fekner MSc , Damian Kasiński MSc , Marta Rasmus MSc , Filip Kowalski MD, PhD , Milena Świtońska Assoc. Prof. , Katarzyna Sierakowska Assoc. Prof. , Tomasz Drewa Prof. , Marta Pokrywczyńska Prof.","doi":"10.1016/j.nano.2025.102828","DOIUrl":"10.1016/j.nano.2025.102828","url":null,"abstract":"<div><div>Diagnosing prostate cancer (PCa) and risk-stratifying patients remains challenging, as PSA-based methods lack precision for active surveillance (AS) decision-making. Extracellular vesicles (EVs) are membranous nano-sized vesicles released by all types of cells and may contain potentially interesting material for diagnostic procedures for PCa.</div><div>This study analyzed surface markers and miRNA profiles of medium-sized plasma EVs (mEVs) from 24 PCa patients using nanoflow cytometry and miRNA profiling. The ratio of PSMA+ EVs to PSMA+CD9+ EVs differed significantly between AS and non-AS patients. Additionally, miR-99a-5p, miR-125b-5p, miR-145-5p, and miR-365a-3p levels were higher in non-AS patients.</div><div>These findings suggest that plasma-derived PSMA+ mEVs originate from the prostate and may serve as biomarkers for PCa progression. Nanoflow cytometry-based analysis of EV surface markers combined with miRNA profiling provides a novel, non-invasive alternative to PSA measurements. This approach could improve risk stratification and decision-making for AS patients, potentially leading to better outcomes.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"67 ","pages":"Article 102828"},"PeriodicalIF":4.2,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0